Shanghai Fosun Pharmaceutical (02196): Detrol tablets and Detrol granules received regulatory approval.

Shanghai Fosun Pharmaceutical (02196) announced that its subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has obtained approval from the National Medical Products Administration for the registration of Desferal Tablets and Desferal Granules. These drugs are chemical products independently developed by the Group (including the Company and its subsidiaries/units) and are approved for the treatment of (1) chronic iron overload in beta-Thalassemia patients over 2 years old due to frequent blood transfusions, and (2) chronic iron overload in non-transfusion dependent Thalassemia patients aged 10 and above. As of September 2025, the Group's cumulative research and development investment for these drugs is approximately RMB 24.55 million (unaudited). According to the latest data from IQVIA CHPA, the sales of Deferoxamine formulations in China (excluding Hong Kong, Macao, and Taiwan) were approximately RMB 12.8 million in 2024.